Literature DB >> 9439577

The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter.

M M Kadrofske1, K P Openo, J L Wang.   

Abstract

Galectin-3 is a beta-galactoside-specific lectin that is a pre-mRNA splicing factor. Here we report the genomic organization of the human LGALS3 (galectin-3) gene and functional characterization of the promoter. Southern blot analysis of genomic DNA revealed that galectin-3 is coded by a single gene in the human genome. The gene is composed of six exons and five introns, spanning a total of approximately 17 kilobases (kb). Based on primer extension and ribonuclease protection analyses, there are two transcription initiation sites located 52 and 50 nucleotides (nt) upstream of the exon I-intron 1 border, and defined here as +1a and +1b, respectively. The translation start site is in exon II. The ribonucleoprotein-like N-terminal domain, containing the proline-glycine-alanine-tyrosine (PGAY) repeat motif, is found entirely within exon III. The carbohydrate recognition sequence is found entirely within exon V. Genomic fragments encompassing -836 to +141 nt (relative to +1a) have significant promoter activity when linked to the luciferase reporter gene and transiently transfected into HeLa cells or human diploid fibroblasts. Quiescent fibroblasts have low promoter activity but the activity increases 100-fold following serum addition. Serum responsive activation regions in the promoter are located between -513 and -339 nt and between -339 and -229 nt; an additional activation region may be located between -105 and -15 nt. Because galectin-3 is an immediate-early gene whose expression is dependent on the proliferative state of the cell, this study provides the basis for determining the molecular mechanisms of transcriptional regulation in neoplasia or cellular senescence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9439577     DOI: 10.1006/abbi.1997.0447

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  31 in total

Review 1.  Galectin genes: regulation of expression.

Authors:  Lorenzo Chiariotti; Paola Salvatore; Rodolfo Frunzio; Carmelo B Bruni
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation.

Authors:  Ruth Saez-Maleta; Ana Merino-Merino; Simon Gundin-Menendez; Ricardo Salgado-Aranda; Daniel AlKassam-Martinez; Virginia Pascual-Tejerina; Javier Martin-Gonzalez; Javier Garcia-Fernandez; Jose-Angel Perez-Rivera
Journal:  Mol Biol Rep       Date:  2021-01-23       Impact factor: 2.316

3.  Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.

Authors:  Barbara Cecchinelli; Luca Lavra; Cinzia Rinaldo; Stefano Iacovelli; Aymone Gurtner; Alessandra Gasbarri; Alessandra Ulivieri; Fabrizio Del Prete; Maria Trovato; Giulia Piaggio; Armando Bartolazzi; Silvia Soddu; Salvatore Sciacchitano
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.

Authors:  Fenglei Wu; Nan Hu; Yu Li; Baoxiang Bian; Guanghui Xu; Yitong Zheng
Journal:  Cell Oncol (Dordr)       Date:  2012-04-03       Impact factor: 6.730

5.  Analysis of variants at LGALS3 single nucleotide polymorphism loci in skull base chordoma.

Authors:  Kaibing Tian; Liang Wang; Ke Wang; Junpeng Ma; Da Li; Yang Yang; Guijun Jia; Zhen Wu; Liwei Zhang; Junting Zhang
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

Review 6.  How galectins have become multifunctional proteins.

Authors:  Gabriel García Caballero; Herbert Kaltner; Tanja J Kutzner; Anna-Kristin Ludwig; Joachim C Manning; Sebastian Schmidt; Fred Sinowatz; Hans-Joachim Gabius
Journal:  Histol Histopathol       Date:  2020-01-10       Impact factor: 2.303

7.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

8.  Distinct effects on splicing of two monoclonal antibodies directed against the amino-terminal domain of galectin-3.

Authors:  Richard M Gray; Michael J Davis; Katherine M Ruby; Patricia G Voss; Ronald J Patterson; John L Wang
Journal:  Arch Biochem Biophys       Date:  2008-04-18       Impact factor: 4.013

9.  Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Authors:  Alexandra A Mourad-Zeidan; Vladislava O Melnikova; Hua Wang; Avraham Raz; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

10.  Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3.

Authors:  M Guévremont; J Martel-Pelletier; C Boileau; F-T Liu; M Richard; J-C Fernandes; J-P Pelletier; P Reboul
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.